Dyne Therapeutics maintains a strong $1.1B cash position, funding operations into mid-2028 despite heavy R&D and operating ...

HARMONIA trial will assess multi-system efficacy, safety and tolerability of z-basivarsen in DM1 -- 48-week trial will enroll approximately 150 ...

Dyne Therapeutics started the new year with proof-of-concept clinical data for experimental genetic medicines addressing two rare muscle diseases—one of which has no FDA-approved treatments. Now the ...

Shares of Dyne Therapeutics (NASDAQ:DYN) plunged 23% after the biotech firm announced changes to its regulatory strategy for DYNE-101, a treatment for myotonic dystrophy type 1 (DM1), following a ...

Monday, Dyne Therapeutics Inc (NASDAQ:DYN) released clinical data from its ongoing Phase 1/2 ACHIEVE trial of DYNE-101 in patients with myotonic dystrophy type 1 (DM1) and its ongoing Phase 1/2 ...

The last time I wrote about Dyne Therapeutics (DYN) it was with respect to a Seeking Alpha article entitled "Dyne: H2 2024 Muscle Disease Data Could Boost Value". In this article, I noted about the ...

- Based on Type C meeting and new data, Dyne submitted revised ACHIEVE trial protocol to FDA elevating vHOT to primary endpoint for U.S. Accelerated Approval - - New positive clinical data from Phase ...

- On Track to Report Initial Data from the Global, Multiple Ascending Dose Phase 1/2 ACHIEVE Clinical Trial in the Second Half of 2023 - “Receiving FDA orphan drug designation for DYNE-101 underscores ...

Dyne Therapeutics, Inc. (NASDAQ:DYN) stock is trading lower after the company announced on Tuesday that it had revised the ongoing Registrational Expansion Cohort in the Phase 1/2 ACHIEVE trial for ...

- In Phase 1/2 ACHIEVE Trial, DYNE-101 Demonstrated Dose Dependent 27% Mean Splicing Correction Across All Patients in the 5.4 mg/kg Cohort at 3 Months - - DYNE-101 Showed Improvement in Myotonia, ...